Skip to main content
Clinical Trials/NCT02029625
NCT02029625
Completed
Phase 1

A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers

NVP Healthcare1 site in 1 country41 target enrollmentFebruary 2014

Overview

Phase
Phase 1
Intervention
NVP-1205
Conditions
Dyslipidemia
Sponsor
NVP Healthcare
Enrollment
41
Locations
1
Primary Endpoint
AUClast
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.

Detailed Description

rosuvastatin and ezetimibe(anti-dyslipidemia)

Registry
clinicaltrials.gov
Start Date
February 2014
End Date
March 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Sponsor
NVP Healthcare
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy male subjects age between 19 and 55 signed informed consent

Exclusion Criteria

  • subjects have a history of allergy reaction of this drug or other drugs

Arms & Interventions

NVP-1205

administration of NVP-1205(rosuvastatin+ezetimibe)

Intervention: NVP-1205

rosuvastatin and ezetimibe

coadministration of rosuvastatin and ezetimibe

Intervention: rosuvastatin and ezetimibe

Outcomes

Primary Outcomes

AUClast

Time Frame: 0-96hr

Secondary Outcomes

  • AUCinf(0-96hr)

Study Sites (1)

Loading locations...

Similar Trials